aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig
Company profile
Ticker
ALRN
Exchange
Website
CEO
Manuel C. Aivado
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Lung Therapeutics, LLC • Lung Therapeutics Australia Pty Ltd • Lung Therapeutics Limited ...
ALRN stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
1 May 24
424B5
Prospectus supplement for primary offering
1 May 24
S-8
Registration of securities for employees
1 May 24
FWP
Free writing prospectus
1 May 24
8-K
Results of Operations and Financial Condition
1 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
8-K
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
15 Apr 24
10-K
2023 FY
Annual report
15 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
Transcripts
Latest ownership filings
4
Change in insider ownership
1 May 24
3
Initial statement of insider ownership
30 Apr 24
144
Notice of proposed sale of securities
29 Apr 24
SC 13D/A
Satter Muneer A
16 Apr 24
4/A
RICKENBACH JOSEF H VON
10 Apr 24
4/A
Reinhard J. Ambros
10 Apr 24
3
Charles Garner
2 Apr 24
4
JAMES BRIAN WINDSOR
6 Mar 24
SC 13G
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO
5 Mar 24
SC 13D/A
Satter Muneer A
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.09 mm | 12.09 mm | 12.09 mm | 12.09 mm | 12.09 mm | 12.09 mm |
Cash burn (monthly) | 366.00 k | (no burn) | 661.00 k | 1.14 mm | 546.67 k | 1.15 mm |
Cash used (since last report) | 2.70 mm | n/a | 4.87 mm | 8.41 mm | 4.03 mm | 8.49 mm |
Cash remaining | 9.40 mm | n/a | 7.22 mm | 3.69 mm | 8.07 mm | 3.60 mm |
Runway (months of cash) | 25.7 | n/a | 10.9 | 3.2 | 14.8 | 3.1 |
Institutional ownership, Q2 2023
14.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 0 |
Closed positions | 3 |
Increased positions | 4 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 1.80 bn |
Total shares | 2.46 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Novartis Bioventures | 1.20 mm | $765.00 k |
Satter Management | 830.47 k | $1.49 bn |
Biotechnology Value Fund L P | 236.84 k | $0.00 |
Geode Capital Management | 55.05 k | $98.53 mm |
Vanguard | 40.47 k | $72.45 mm |
Blair William & Co | 29.67 k | $53.10 mm |
KCK | 22.34 k | $39.99 mm |
HighTower Advisors | 19.20 k | $34.00 mm |
Renaissance Technologies | 15.86 k | $28.00 k |
Tower Research Capital | 3.74 k | $6.70 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 May 24 | University Of Texas/texas Am Investment Managment | Common Stock | Sell | Dispose S | No | No | 4.32 | 25 | 108.00 | 1,779,306 |
1 May 24 | University Of Texas/texas Am Investment Managment | Common Stock | Sell | Dispose S | No | No | 4.29 | 2,903 | 12.45 k | 1,779,331 |
1 May 24 | University Of Texas/texas Am Investment Managment | Common Stock | Sell | Dispose S | No | No | 4.285 | 200 | 857.00 | 1,782,234 |
1 May 24 | University Of Texas/texas Am Investment Managment | Common Stock | Sell | Dispose S | No | No | 4.28 | 337 | 1.44 k | 1,782,434 |
1 May 24 | University Of Texas/texas Am Investment Managment | Common Stock | Sell | Dispose S | No | No | 4.275 | 200 | 855.00 | 1,782,771 |
1 May 24 | University Of Texas/texas Am Investment Managment | Common Stock | Sell | Dispose S | No | No | 4.27 | 100 | 427.00 | 1,782,971 |
1 May 24 | University Of Texas/texas Am Investment Managment | Common Stock | Sell | Dispose S | No | No | 4.265 | 317 | 1.35 k | 1,783,071 |
1 May 24 | University Of Texas/texas Am Investment Managment | Common Stock | Sell | Dispose S | No | No | 4.26 | 310 | 1.32 k | 1,783,388 |
1 May 24 | University Of Texas/texas Am Investment Managment | Common Stock | Sell | Dispose S | No | No | 4.25 | 7,923 | 33.67 k | 1,783,698 |
1 May 24 | University Of Texas/texas Am Investment Managment | Common Stock | Sell | Dispose S | No | No | 4.18 | 400 | 1.67 k | 1,791,621 |
News
Aileron Therapeutics Announces Data From Cohort 1 Of Phase 1b Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis
1 May 24
12 Health Care Stocks Moving In Thursday's Intraday Session
18 Apr 24
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
18 Apr 24
Ladenburg Thalmann Maintains Buy on Aileron Therapeutics, Raises Price Target to $19
18 Apr 24
Aileron Therapeutics Q4 EPS $(1.54) Down From $(1.00) YoY; Cash Runway Expected To Fund Operations And Key Milestones Into Q4 Of 2024
15 Apr 24
Press releases
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
3 May 24
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
1 May 24
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
1 May 24
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
15 Apr 24